Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on NPS Pharmaceuticals

Related NPSP
NPS Pharma Initiates Phase 2a Study Of NPSP795 In Adult Patients With Autosomal Dominant Hypocalcemia (ADH)
NPS Pharma's Natpara Likely To Be Reviewed In September - Analyst Blog

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on NPS Pharmaceuticals (NASDAQ: NPSP), and raised its price target from $13.00 to $15.00.

Jefferies noted, “As expected, FDA's AdComm panel voted for recommending approval of Gattex unanimously. Panel also voted favorably on NPSP's proposed REMS (10-1), supporting likely timely approval (PDUFA date, 12/30/12). With potential approval of a 2nd product Natpara in ~mid-2014, we see significant upside in NPSP shares from current levels. Reiterate Buy.”

NPS Pharmaceuticals closed on Tuesday at $10.19.

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (NPSP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters